2024
Evaluation of Strategies for Transitioning to Annual SARS-CoV-2 Vaccination Campaigns in the United States.
Wells C, Pandey A, Moghadas S, Fitzpatrick M, Singer B, Galvani A. Evaluation of Strategies for Transitioning to Annual SARS-CoV-2 Vaccination Campaigns in the United States. Annals Of Internal Medicine 2024, 177: 609-617. PMID: 38527289, DOI: 10.7326/m23-2451.Peer-Reviewed Original ResearchSARS-CoV-2 vaccination campaignSARS-CoV-2Centers for Disease Control and PreventionDisease Control and PreventionSARS-CoV-2 vaccinesHealth care costsVaccine-acquired immunityFood and Drug AdministrationU.S. Food and Drug AdministrationControl and PreventionNational Institutes of HealthVaccination campaignInfluenza vaccineInitial doseInstitutes of HealthSARS-CoV-2 variantsBooster doseImmune evasionDrug AdministrationUnited StatesNotsew Orm Sands FoundationDoseHealthPopulation immunityNational InstituteImpact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study
Shoukat A, Bawden C, Röst G, LeBlanc J, Galvani A, Langley J, Moghadas S. Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study. Vaccine 2024, 42: 1768-1776. PMID: 38368226, DOI: 10.1016/j.vaccine.2024.02.041.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioQuality-adjusted life yearsLong-term care homesCommunity-dwelling older adultsCanadian Immunization Research NetworkIncremental cost-effectiveness ratio valuesResidents of long-term care homesRSV diseaseOlder adultsBurden of RSV diseaseRespiratory syncytial virus diseaseNo-vaccination scenarioRSV-related hospitalisationNo vaccinesRespiratory syncytial virusVaccination programBudget impactSocietal perspectiveCost-effectiveness ratioReduction of hospitalizationInfluenza vaccineRSV seasonSyncytial virusHealth benefitsAnalysis of vaccination
2009
Optimizing Influenza Vaccine Distribution
Medlock J, Galvani AP. Optimizing Influenza Vaccine Distribution. Science 2009, 325: 1705-1708. PMID: 19696313, DOI: 10.1126/science.1175570.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedCenters for Disease Control and Prevention, U.S.ChildChild, PreschoolDisease OutbreaksHealth PolicyHumansImmunization ProgramsInfantInfluenza A virusInfluenza A Virus, H1N1 SubtypeInfluenza VaccinesInfluenza, HumanMiddle AgedModels, StatisticalUnited StatesVaccinationYoung AdultConceptsOutcome measuresNovel swine-origin influenzaOptimal vaccine allocationInfluenza vaccine distributionContingent valuationSwine-origin influenzaYears of lifePublic health policyOptimal allocationEconomic costsInfluenza vaccineSeasonal influenzaInfluenza pandemicU.S. CentersVaccine allocationDisease controlMortality dataVaccine distributionHealth policyOptimal vaccinationPolicy optimizationTransmission dynamicsInfluenzaAllocationNew recommendations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply